GDT002 shown to have a potent anti-tumor activity across a broad spectrum of solid and liquid tumors Ovarian cancer selected from broad screening of solid tumor types as the indication for GDT002  Utrecht, Netherlands and Boston, Mass., 28 March 2022: Gadeta B.V. (‘Gadeta’), a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies […]